ATE253376T1 - POLYNUCLEOTIDE VACCINE, PREFERABLY FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLES - Google Patents

POLYNUCLEOTIDE VACCINE, PREFERABLY FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLES

Info

Publication number
ATE253376T1
ATE253376T1 AT97934578T AT97934578T ATE253376T1 AT E253376 T1 ATE253376 T1 AT E253376T1 AT 97934578 T AT97934578 T AT 97934578T AT 97934578 T AT97934578 T AT 97934578T AT E253376 T1 ATE253376 T1 AT E253376T1
Authority
AT
Austria
Prior art keywords
cattles
treatment
respiratory disease
polynucleotide vaccine
vaccine
Prior art date
Application number
AT97934578T
Other languages
German (de)
Inventor
Jean-Christophe Audonnet
Annabelle Bouchardon
Philippe Baudu
Michel Riviere
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Application granted granted Critical
Publication of ATE253376T1 publication Critical patent/ATE253376T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/813Viral vaccine for bovine species, e.g. cattle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97934578T 1996-07-19 1997-07-16 POLYNUCLEOTIDE VACCINE, PREFERABLY FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLES ATE253376T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609403A FR2751229B1 (en) 1996-07-19 1996-07-19 POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE
PCT/FR1997/001325 WO1998003200A2 (en) 1996-07-19 1997-07-16 Polynucleotide vaccine formula, particularly for treating bovine respiratory disease

Publications (1)

Publication Number Publication Date
ATE253376T1 true ATE253376T1 (en) 2003-11-15

Family

ID=9494497

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03016996T ATE307607T1 (en) 1996-07-19 1997-07-16 POLYNUCLEOTIDE VACCINE, PREFERABLY FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLES
AT97934578T ATE253376T1 (en) 1996-07-19 1997-07-16 POLYNUCLEOTIDE VACCINE, PREFERABLY FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03016996T ATE307607T1 (en) 1996-07-19 1997-07-16 POLYNUCLEOTIDE VACCINE, PREFERABLY FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLES

Country Status (29)

Country Link
US (2) US6376473B1 (en)
EP (2) EP1382348B1 (en)
JP (1) JP2000516200A (en)
AP (1) AP9701044A0 (en)
AR (1) AR007862A1 (en)
AT (2) ATE307607T1 (en)
AU (1) AU734442B2 (en)
BR (1) BR9710506A (en)
CA (1) CA2260855C (en)
CO (1) CO4700306A1 (en)
CZ (2) CZ298898B6 (en)
DE (2) DE69734483T2 (en)
DK (2) DK0912194T3 (en)
ES (2) ES2254833T3 (en)
FR (1) FR2751229B1 (en)
HR (1) HRP970383A2 (en)
HU (2) HU225169B1 (en)
ID (1) ID19513A (en)
IL (2) IL127703A0 (en)
MA (1) MA24269A1 (en)
NZ (4) NZ517686A (en)
PE (1) PE84699A1 (en)
PL (1) PL190122B1 (en)
PT (1) PT912194E (en)
PY (1) PY970078A (en)
RU (1) RU2305560C2 (en)
UA (1) UA70914C2 (en)
WO (1) WO1998003200A2 (en)
ZA (1) ZA976283B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751229B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
FR2804028B1 (en) * 2000-01-21 2004-06-04 Merial Sas IMPROVED DNA VACCINES FOR PENSION ANIMALS
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
MXPA06009452A (en) 2004-02-19 2007-03-15 Univ Alberta Leptin promoter polymorphisms and uses thereof.
PT1881845E (en) 2005-04-25 2010-05-31 Merial Ltd Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
UA100692C2 (en) 2007-05-02 2013-01-25 Мериал Лимитед Dna-plasmids having increased expression and stability
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
RU2559527C2 (en) 2008-11-28 2015-08-10 Мериал Лимитед Recombinant vaccine against avian flu and application thereof
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
CN103260643A (en) 2009-12-28 2013-08-21 梅里亚有限公司 Recombinant ndv antigen and uses thereof
CN102947341B (en) 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 Engineered opsonins for pathogen detection and treatment
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
ES2617743T3 (en) 2010-03-12 2017-06-19 Merial, Inc. Recombinant vaccines of the bluetongue virus and its uses
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
AR084358A1 (en) * 2010-12-27 2013-05-08 Lilly Co Eli COMPOSITIONS AND METHODS FOR IDENTIFYING AND DIFFERING VIRAL COMPONENTS OF MULTIVALENT VACCINES OF THE “BOILING FEVER” (BOVINE RESPIRATORY DISEASE COMPLEX (BRDC))
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
HK1200329A1 (en) 2011-04-25 2015-08-07 先进生物学实验室股份有限公司 Truncated hiv envelope proteins (env), methods and compositions related thereto
ES2764079T3 (en) 2011-05-27 2020-06-02 Boehringer Ingelheim Animal Health Usa Inc Genetic vaccines against Hendra virus and Nipah virus
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
SI2741740T1 (en) 2011-08-12 2017-08-31 Merial, Inc. Vacuum-assisted preservation of biological products, in particular of vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
ES2632429T3 (en) 2012-02-14 2017-09-13 Merial, Inc. Subunit rotavirus vaccines and procedures for the manufacture and use thereof
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2664069T3 (en) 2012-06-13 2018-04-18 Merial, Inc. BTV and AHSV vaccines of rearranged genome
MY171498A (en) 2012-08-01 2019-10-15 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHODS AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR CAPTURE OF A TARGET ENTITY
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
DK3313864T3 (en) 2015-06-23 2021-11-01 Boehringer Ingelheim Animal Health Usa Inc RECOMBINANT VIRUS VECTORS CONTAINING PRRSV MINOR PROTEIN AND METHODS OF MANUFACTURE AND USE
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
FI3355915T3 (en) 2015-09-29 2024-01-12 Boehringer Ingelheim Animal Health Usa Inc Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
MA42640B1 (en) 2015-11-23 2021-06-30 Merial Inc Dmdv and e2 fusion proteins and their uses
TWI760322B (en) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 Recombinant adenovirus vectored fmdv vaccines and uses thereof
CN109021081B (en) * 2018-08-10 2019-06-04 山东大学 A kind of bovine viral diarrhea virus-like particle and its construction method and application

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU611784B2 (en) * 1988-04-22 1991-06-20 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
AU650040B2 (en) * 1990-07-24 1994-06-09 Uab Research Foundation, The Methods of use of bovine respiratory syncytial virus recombinant DNA, proteins vaccines, antibodies, and transformed cells
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
ATE475668T1 (en) * 1994-01-27 2010-08-15 Univ Massachusetts Medical IMMUNIZATION BY VACCINATION OF DNA TRANSCRIPTION UNIT
US5541102A (en) * 1994-09-02 1996-07-30 Board Of Regents, University Of Nebraska-Lincoln Bovine cell line resistant to in vitro infection by bovine viral diarrhea virus and all other known pestiviruses
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060457A (en) 1996-06-20 2000-05-09 Universite De Montreal DNA plasmid vaccine for immunization of animals against BVDV
FR2751229B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE
JP5566663B2 (en) * 2009-11-09 2014-08-06 三菱重工業株式会社 Multiblade centrifugal fan and air conditioner using the same

Also Published As

Publication number Publication date
UA70914C2 (en) 2004-11-15
CO4700306A1 (en) 1998-12-29
AP9701044A0 (en) 1997-07-31
ES2254833T3 (en) 2006-06-16
FR2751229B1 (en) 1998-11-27
DE69734483D1 (en) 2005-12-01
CZ17599A3 (en) 1999-06-16
EP1382348A2 (en) 2004-01-21
MA24269A1 (en) 1998-04-01
NZ517686A (en) 2003-01-31
PL331236A1 (en) 1999-07-05
PL190122B1 (en) 2005-11-30
DE69725988T2 (en) 2004-11-11
ID19513A (en) 1998-07-16
EP1382348B1 (en) 2005-10-26
ZA976283B (en) 1999-01-19
IL127703A0 (en) 1999-10-28
WO1998003200A3 (en) 1998-02-26
RU2305560C2 (en) 2007-09-10
PY970078A (en) 2001-12-03
WO1998003200A2 (en) 1998-01-29
EP1382348A3 (en) 2004-01-28
DE69734483T2 (en) 2006-07-20
ES2210548T3 (en) 2004-07-01
AU3773597A (en) 1998-02-10
DK0912194T3 (en) 2004-03-15
CA2260855C (en) 2012-01-03
CZ298898B6 (en) 2008-03-05
RU2002132831A (en) 2005-01-20
NZ333751A (en) 2001-03-30
IL127703A (en) 2006-12-31
HU228353B1 (en) 2013-03-28
HUP9902791A2 (en) 1999-12-28
CZ298915B6 (en) 2008-03-12
HU0500910D0 (en) 2005-11-28
FR2751229A1 (en) 1998-01-23
AR007862A1 (en) 1999-11-24
US20020160018A1 (en) 2002-10-31
JP2000516200A (en) 2000-12-05
AU734442B2 (en) 2001-06-14
US6376473B1 (en) 2002-04-23
DE69725988D1 (en) 2003-12-11
EP0912194A2 (en) 1999-05-06
HRP970383A2 (en) 1998-10-31
DK1382348T3 (en) 2006-03-13
HUP9902791A3 (en) 2000-03-28
PE84699A1 (en) 1999-11-28
NZ508939A (en) 2002-04-26
PT912194E (en) 2004-03-31
EP0912194B1 (en) 2003-11-05
US6818628B2 (en) 2004-11-16
HU225169B1 (en) 2006-07-28
CA2260855A1 (en) 1998-01-29
BR9710506A (en) 1999-08-17
ATE307607T1 (en) 2005-11-15
NZ508940A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
ATE253376T1 (en) POLYNUCLEOTIDE VACCINE, PREFERABLY FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLES
DE59712045D1 (en) DEVICE FOR TREATING THE HEART
DE69739303D1 (en) DEVICE FOR THE THERMAL TREATMENT OF TISSUE
DE69734778D1 (en) POLYNUCLEOTIDE VACCINE FORMULATION AGAINST HORSE DISEASES
DE60023128D1 (en) PYRAZOLECARBOXAMIDE FOR THE TREATMENT OF FATIBILITY AND OTHER DISEASES
DE69827424D1 (en) Device for the controlled thermal treatment of tissue
ATE247987T1 (en) TREATMENT TO ELIMINATE ODORS
DE69924750D1 (en) DEVICE FOR THE THERMAL TREATMENT OF TISSUE
DE69731309D1 (en) Vaccine formula based on polynucleotide for the treatment of dog diseases, especially those of the respiratory and digestive tract
DE69918687D1 (en) 4-PHENYLPIPERIDINE FOR THE TREATMENT OF PRUTITIC SKIN DISEASES
ATE241977T1 (en) USE OF ANTI-MICROTUBULAR AGENTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
DE69734284D1 (en) COMPOSITION OF A POLYNUCLEOTIDE VACCINE FOR THE TREATMENT OF RESPIRATORY AND REPRODUCTIVE DISEASES OF THE PIG
DE69737590D1 (en) WATER ABSORBENT PRODUCT AND METHOD FOR ITS MANUFACTURE
DE69711311D1 (en) Device for the thermal treatment of tissue
DE69820997D1 (en) COMPOSITIONS AND METHODS FOR TREATING THE INCREASED EYES PRINTOUT
NO975690L (en) Procedure for improving animal health
FR2718037B1 (en) Tumor treatment apparatus.
GB2319725B (en) Extracting particles produced by the treating of human or animal nails
ATE347372T1 (en) VACCINES FOR THE TREATMENT OF MYCOSIS
DE59707096D1 (en) Hair treatment agent for setting the hair
DE69519602D1 (en) Spherical activated carbon for the treatment of hemorrhoids
DE69822297D1 (en) TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DE69735417D1 (en) 2,5-DIHYDROXYBENZYLSULFON DERIVATIVES FOR THE TREATMENT OF SEXUAL DISORDERS
ATE299371T1 (en) ANTICONVULSIVES FOR THE TREATMENT OF AUTISM
DE59704933D1 (en) Use of PHMB for the treatment of tumor diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0912194

Country of ref document: EP